Nanoscale Coordination Polymer Based Nano-Vaccine for Tumor Immunotherapy.
Nanoscale Coordination Polymer Based Nano-Vaccine for Tumor Immunotherapy.
复制标题
DOI：
10.1021/acsnano.9b05974
复制
发表时间：
2019-11
期刊：
影响因子：
17.1
通讯作者：
He Zhao;Jun Xu;Yan Li;Xinxian Guan;Xiao Han;Yunyun Xu;Huiting Zhou;Rui Peng;Jian Wang
中科院分区：
文献类型：
--
作者：
He Zhao;Jun Xu;Yan Li;Xinxian Guan;Xiao Han;Yunyun Xu;Huiting Zhou;Rui Peng;Jian Wang
肿瘤疫苗为癌症治疗提供了强大的免疫力，在肿瘤免疫治疗领域引起了极大的兴趣。本工作以Mn2+离子与核苷酸齐聚结合结构域1(Nod1)激动剂Meso-2，6-二氨基甲酸(DAP)形成的纳米配位聚合物(NCP)为有机配体，包裹模型蛋白抗原卵蛋白(OVA)，制备了一种肿瘤疫苗。所获得的OVA@Mn-DAP纳米粒子可作为一种有效的肿瘤疫苗，通过增加细胞对抗原的摄取和刺激Nod1通路来促进树突状细胞(DC)的成熟及其抗原的交叉递呈。体内磁共振和荧光成像显示，这种OVA@MN-DAP疫苗在局部注射后可以迁移到淋巴结中。重要的是，免疫小鼠不仅可以预防B16-OVA肿瘤的发生，而且如果与抗程序性细胞死亡蛋白-1抗体(α-PD-1)免疫检查点阻断治疗相结合，对已建立的肿瘤的生长也有显著的抑制作用。因此，本工作为构建有效的肿瘤免疫治疗纳米疫苗提供了一个创新平台。
Tumor vaccines to induce robust immunity for cancer treatment have attracted tremendous interests in cancer immunotherapy. In this work, a type of cancer vaccine is prepared by using nanoscale coordination polymer (NCP) formed between Mn2+ ions and a nucleotide oligomerization binding domain 1 (Nod1) agonist, meso-2,6-diaminopimelic acid (DAP), as the organic ligand, to encapsulate a model protein antigen, ovalbumin (OVA). The obtained OVA@Mn-DAP nanoparticles could act as an effective tumor vaccine to promote the maturation of dendritic cells (DCs) as well as their antigen cross-presentation via increasing the cellular uptake of antigen and stimulating Nod1 pathway with DAP. Such OVA@Mn-DAP vaccine could migrate into lymph nodes after local injection, as revealed by in vivo magnetic resonance (MR) and fluorescence imaging. Importantly, vaccination with OVA@Mn-DAP could not only offer prophylactic to protect mice from challenged B16-OVA tumors, but also result in significant therapeutic effect to inhibit growth of already-established tumors if in combination with anti-programmed cell death protein 1 antibody (α-PD-1) immune checkpoint blockade therapy. Therefore, this work presents an innovative platform to construct effective nano-vaccine for tumor immunotherapy.